Imatron receives four scanner orders
Imatron of South San Francisco, CA, has received orders for four ultrafast CT scanners, the company reported this month. Two of the systems were shipped in the fourth quarter of 1997 and were sent to the Cardioguard Clinic in Sarasota, FL, and the
Imatron of South San Francisco, CA, has received orders for four ultrafast CT scanners, the company reported this month. Two of the systems were shipped in the fourth quarter of 1997 and were sent to the Cardioguard Clinic in Sarasota, FL, and the Cardiovascular Institute Dedinje in Belgrade, Yugoslavia.
The other two orders will be shipped this quarter to Cedars-Sinai Medical Center in Los Angeles and to a Cardioguard Clinic being planned for Orlando. Cardioguard intends to open a total of six ultrafast CT centers in Florida in the next 18 months. The systems were ordered through Imatron's distributor, Siemens Medical Systems of Iselin, NJ, which is giving up rights to Imatron's scanners in April under an agreement reached between the companies late last year (SCAN Special Report 12/97).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
